InvestSMART

NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) - Announcements

Current share price for NSB : $0.060 0.001 (1.64%)+

ASX company news and announcements for NeuroScientific Biopharmaceuticals Ltd (NSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All NeuroScientific Biopharmaceuticals Ltd (NSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than NeuroScientific Biopharmaceuticals Ltd (NSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for NeuroScientific Biopharmaceuticals Ltd (NSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$23 Notification of cessation of securities - NSB 1 Jul 2026 9:56AM $0.059 $0.060 risen by 1.69%
$23 Escrowed Securities Update 19 Jun 2026 1:12PM $0.063 $0.060 fallen by 4.76%
$23 Investor Webinar 11 Jun 2026 12:50PM $0.059 $0.060 risen by 1.69%
$23 Change in substantial holding 9 Jun 2026 8:21AM $0.087 $0.060 fallen by 31.03%
$23 Becoming a substantial holder 3 Jun 2026 5:26PM $0.091 $0.060 fallen by 34.07%
$23 Change of Director's Interest Notice x2 2 Jun 2026 5:41PM $0.093 $0.060 fallen by 35.48%
$23 Section 708A Notice 1 Jun 2026 5:35PM $0.090 $0.060 fallen by 33.33%
$23 Application for quotation of securities - NSB 1 Jun 2026 5:30PM $0.090 $0.060 fallen by 33.33%
$23 Updated Presentation - Successful Results 26 May 2026 12:17PM $0.110 $0.060 fallen by 45.45%
$23 Remarkable Results from Patients treated with StemSmart 26 May 2026 9:30AM $0.094 $0.060 fallen by 36.17%
$23 Trading Halt 25 May 2026 9:44AM $0.094 $0.060 fallen by 36.17%
$23 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2026 8:46AM $0.110 $0.060 fallen by 45.45%
$23 StemSmart Manufacturing Scale-Up Transfer Advances 17 Mar 2026 9:38AM $0.088 $0.060 fallen by 31.82%
$23 Half Yearly Report and Accounts 25 Feb 2026 7:00PM $0.110 $0.060 fallen by 45.45%
$23 Company Presentation 16 Feb 2026 9:53AM $0.130 $0.060 fallen by 53.85%
$23 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2026 8:27AM $0.135 $0.060 fallen by 55.56%
$23 Successful Clinical Results Achieved under Special Access 13 Jan 2026 9:51AM $0.115 $0.060 fallen by 47.83%
$23 Trading Halt 9 Jan 2026 9:27AM $0.115 $0.060 fallen by 47.83%
$23 Results of Annual General Meeting 12 Nov 2025 3:06PM $0.135 $0.060 fallen by 55.56%
$23 Investor Webinar Update 12 Nov 2025 10:00AM $0.135 $0.060 fallen by 55.56%
$23 Fourth Patient Commences StemSmart MSC Treatment 11 Nov 2025 9:26AM $0.140 $0.060 fallen by 57.14%
$23 Clinical & Scientific Advisory Board Appointed 6 Nov 2025 9:28AM $0.125 $0.060 fallen by 52%
$23 Quarterly Activities/Appendix 4C Cash Flow Report 30 Oct 2025 9:10AM $0.115 $0.060 fallen by 47.83%
$23 AusBiotech Presentation 21 Oct 2025 9:23AM $0.140 $0.060 fallen by 57.14%
$23 First Patients Approved for Special Access Program 7 Oct 2025 9:27AM $0.155 $0.060 fallen by 61.29%

1 - 25 of 407 results

Page 1 of 17

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.